
# **ACLF and Liver Transplantation**

Kimberly Brown, MD, FAASLD, FAST, AGAF
Professor of Medicine Wayne State University
Chief Division of Gastroenterology and Hepatology
Associate Medical Director Henry Ford Transplant Institute
Henry Ford Hospital, Detroit



## ACLF vs Decompensation in Cirrhosis



# ACLF: A Syndrome

- Acute decompensation in hospitalized patients with cirrhosis
  - -New onset HE
  - -Recent onset of ascites
  - -GI bleeding
  - -Infection
- Intense systemic inflammatory response
- Single or multiple organ failure
- Close association with precipitating event
  - -Infection
  - -Alcohol associated hepatitis
- High 28 day mortality

#### HENRY FORD HEALTH.

### What Is ACLF Grading and CLIF-SOFA Score?

#### **ACLF**

- ACLF describes the syndrome characterized by acute decompensation of cirrhosis, organ failure, and high short-term mortality<sup>1</sup>
  - Seen in ~30% of patients with decompensated cirrhosis¹
  - Can be triggered by sepsis, alcohol use,
     and the relapse of chronic viral hepatitis, as
     well as many unidentifiable causes<sup>2</sup>
  - -Thought to develop via an excessive systemic inflammatory response<sup>2</sup>

# **Chronic Liver Failure-Sequential Organ Failure Assessment (CLIF-SOFA) Score**

- CLIF-SOFA score was developed to predict mortality risk in patients with ACLF<sup>1,2</sup>
  - -Using this scoring system, patients are categorized as being ACLF grade 1, 2, or 3 based on the number of organ system failing<sup>2</sup>
  - Higher ACLF grades are associated with higher mortality<sup>2</sup>

# ACLF is Different than Acute Decompensation

- ACLF has
  - -Higher mortality
  - -More alcohol, infection or more than one trigger
  - -More inflammation
  - -Differences in metabolic reprogramming
  - -Abnormal mitochondria
  - -Change in microbiome





# ACLF: Multiple Organ Failure Definitions

• Syndrome Characterized by high short-term mortality in patients with cirrhosis associated with hepatic +/- extrahepatic organ failure

	NACSELD	EASL-CLIF	APASL AARC
Liver		Bilirubin ≥ 12 mg/dL	Bilirubin ≥ 15 mg/dL
Kidney	RRT	$Cr \ge 2 mg/dL or RRT$	Cr ≥ 1.5 mg/dL
Brain (HE)	III-IV	III-IV	I-IV
Circulatory	Inotropes	Inotropes	<b>Lactate</b> ≥ <b>1.5</b>
Respiratory	BiPAP/Ventilator	BiPAP/Ventilator	
Coagulation		INR ≥ 2.5	INR ≥ 1.8



## **CLIF-SOFA Score**

Organ System	Variable			
Liver	Bilirubin (mg/dl)	< 6.0	<u>&gt;</u> 6 to < 12	<u>&gt;</u> 12
Kidney	Creatinine (mg/dl)	< 2.0	≥ 2.0 to < 3.5	≥ 3.5 or RRT
Cerebral	HE grade (West Haven criteria)	0	I-II	III-IV or intubation for HE
Coagulation	INR	< 2.0	<u>&gt;</u> 2.0 to < 2.5	<u>&gt;</u> 2.5
Circulation	MAP (mm Hg)	<u>&gt;</u> 70	< 70	Use of vasopressors
Respiration	PaO2/FiO2 SpO2/FiO2	> 300 > 357	>200 to < 300 > 214 to < 357	≤ 200 ≤ 214 Or use of mechanical ventilation



## **ACLF Definitions**

- ACLF 1
  - Single organ kidney failure
  - Single liver, coag, circulatory or lung failure with Cr 1.5-1.9 or HE grade 1 or 2 or both
  - Single brain failure with cr 1.5-1.9
- ACLF 2
  - 2 organ failures
- ACLF 3
  - 3 organ failures



Acute Decompensation Mortality Lower than ACLF 70 |


**Triggers** 

Bacterial infection 35%

• GIB 22%


Acute alcohol 19%

Kidney dysfunction Most common organ Failure 49%






# Relationship between probability of death at 28 days and leukocyte count according to Presence of ACLF and prior history of AD





## Mortality Based on ACLF Grade




**28-DAY MORTALITY** 





90-DAY MORTALITY

### **Bacterial Infection in Cirrhosis**



# Prevalence and Incidence of Bacterial Infection in ACLF





HENRY FORD HEALTH.

Transplant

Moreau, Gastro 2013, Trebicka, J Hep 2022 Fernandez, Gut 2018

# Pathogenesis of ACLF: Impact of Infection

Arroyo, Nat Rev Nephrol 2011


**Bacterial Infection** 

Intense Systemic Inflammation
Tissue damage (mitochondrial dysfunction and immunopathology)

## Organ failure


Renal failure
Shock
Jaundice
DIC, Coagulopathy
RAI, CIRCI
Respiratory Failure/ARDS

# 90 Day Transplant -Free Survival AD and ACLF





# Algorithm for Management Cirrhosis and Sepsis




# Liver Transplant for ACLF

- Urgency
- Utility
- Equity




# Waitlist Mortality in Patients with ACLF

#### Death or Removal Within 90 Days of Listing (%)



Gastroenterology


# Probability of staying alive on the waiting list for more than 30 days without transplantation stratified by the number of organ failures



30 day removal from the list because of death or LT: no OF 10%, 1 OF 45%, 2 OF 80%, 3 OF 92%, 4 OF 94%, 5, 6 OF 98%

Sundaram, Gastro 2019, Thuluvath, J Hep 2018


# Survival Benefit of Liver Transplant in ACLF3




# Independent Predictors of 1-Year Patient Survival with ACLF3 at Listing

Covariates	Hazard Ratio (95% CI)
Karnofsky score > 80	0.76 (0.55-1.06)
Futility Score > 8 (ventilator, age > 60, Cr > 1.5, DM, RRT)	1.12 (0.97-1.30)
Circulatory Failure	0.90 (0.78-1.05)
> 3 organ failure	1.04 (0.92-1.19)
Transplant within 30 days of listing	0.89 (0.81-0.98)
DRI <u>&gt;</u> 1.7	1.22 (1.09-1.35)
Mechanical Ventilation	1.49 (1.22-1.84)


# Factors Affecting 1 Year Survival Post OLT in Patients with ACLF















# Survival in High Risk Recipients Comparing Graft Steatosis UNOS Jan 2002- June 2018


UNOS Jan 2002- June 2018 54,956 LT recipients of which 43.6% had ACLF at time of LT

Independent predictors
Recipient age
Pulmonary failure
Brain failure
CV failure
Alcohol liver disease

Tertiles Low risk < 7.55 Medium 7.55-11.57 High risk > 11.57



# Survival in High Risk Recipients Comparing Donor Age and Local vs Regional/National Sharing




# High-risk liver transplant recipients with ACLF 3 should receive the good quality graft

UNOS Jan 2002- June 2018 54,956 LT recipients of which 43.6% had ACLF at time of LT

#### **Validation**

## (A) P=0.49 0.39 < 0.04 Low risk (N=1160) Medium risk (N=1119) High risk (N=1162) ■ DRI<1.5 ■ DRI≥1.5

#### **Whole Dataset**



Singal, Liver International 2022

#### HENRY FORD HEALTH.

**Transplant** 


# Transplant Outcomes Research for ACLF using Registry Data: Limitations

Does not distinguish between new or existing

- Acute decompensation
  - Recent onset ascites
  - -New onset HE
  - -GIB x
  - -Infection X
- Organ Failure
  - -Circulatory failure/ pulmonary failure at listing x
  - -He grade at listing
- Misclassification

#### HENRY FORD HEALTH

# Independent Predictors of Post-Transplant Mortality: Results of the ELITA/EFCLIF Collaborative Study (ECLIS)



# Independent Predictors of Post Transplant Mortality


Covariates2	Hazard Ration (95% CI)	P-Value
Dialysis	2.74 91.37-5.51)	0.005
Lactate > 4 mmol	3.14 (1.37-7.19)	0.007
MDR infection	3.67 (1.63-8.28)	0.002

Belli et al, J Hep 2021 (European)


Odds Ratio	P-Value	
2.24	0.01	15 LT centers 2014-2019 (n=521)
1.80	0.09	
4.05	<0.001	
2.03	0.019	US
1.90	0.02	Model score Superior to MELD
	<ul><li>2.24</li><li>1.80</li><li>4.05</li><li>2.03</li></ul>	2.24       0.01         1.80       0.09         4.05       <0.001



### Resource Utilization







## Conclusions

- ACLF is a distinct entity different from but related to Acute Decompensation in patients with cirrhosis
- Precipitating factors include infection, acute alcohol use most common
- Degree of ACLF influences outcomes
- Liver Transplantation provides survival benefit in patients with ACLF including those with ACLF3
- Post transplant survival is lower in ACLF3 compared with those with ACLF 1 or 2 or no ACLF
- Patients with ACLF have greater post transplant resource utilization
- Careful patient and donor organ quality selection is key for optimal outcomes
- Early recognition and transfer to a liver transplant center is critical

#### HENRY FORD HEALTH.